

Alpha-synuclein biology in Lewy body diseases

Alzheimer's Research and Therapy

6, 73

DOI: [10.1186/s13195-014-0073-2](https://doi.org/10.1186/s13195-014-0073-2)

Citation Report

#	ARTICLE	IF	CITATIONS
1	The associations between Parkinson's disease and cancer: the plot thickens. <i>Translational Neurodegeneration</i> , 2015, 4, 20.	3.6	77
2	Isolation of Endoplasmic Reticulum, Mitochondria, and Mitochondria-Associated Membrane and Detergent Resistant Membrane Fractions from Transfected Cells and from Human Cytomegalovirus-Infected Primary Fibroblasts. <i>Current Protocols in Cell Biology</i> , 2015, 68, 3.27.1-3.27.33.	2.3	61
3	Long-chain omega-3 fatty acids and the brain: a review of the independent and shared effects of EPA, DPA and DHA. <i>Frontiers in Aging Neuroscience</i> , 2015, 7, 52.	1.7	592
4	Direct and/or Indirect Roles for SUMO in Modulating Alpha-Synuclein Toxicity. <i>Biomolecules</i> , 2015, 5, 1697-1716.	1.8	28
5	Alpha-Synuclein as a Mediator in the Interplay between Aging and Parkinson's Disease. <i>Biomolecules</i> , 2015, 5, 2675-2700.	1.8	49
6	Aggregates feel the strain. <i>Nature</i> , 2015, 522, 296-297.	13.7	12
7	Candidate genes for Parkinson disease: Lessons from pathogenesis. <i>Clinica Chimica Acta</i> , 2015, 449, 68-76.	0.5	25
8	SOLOMON: An ontology for Sensory-Onset, Language-Onset and Motor-Onset dementias. , 2015, , .		5
9	Regulation of protein homeostasis in neurodegenerative diseases: the role of coding and non-coding genes. <i>Cellular and Molecular Life Sciences</i> , 2015, 72, 4027-4047.	2.4	29
10	Dimerization propensities of Synucleins are not predictive for Synuclein aggregation. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2015, 1852, 1658-1664.	1.8	15
11	Design, Synthesis, and Characterization of 3-(Benzylidene)indolin-2-one Derivatives as Ligands for β -Synuclein Fibrils. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 6002-6017.	2.9	92
12	Glycogen synthase kinase-3 beta (GSK-3 β) signaling: Implications for Parkinson's disease. <i>Pharmacological Research</i> , 2015, 97, 16-26.	3.1	226
13	Neuroinflammation in Lewy body dementia. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1398-1406.	1.1	68
14	Post-mortem brain analyses of the Lothian Birth Cohort 1936: extending lifetime cognitive and brain phenotyping to the level of the synapse. <i>Acta Neuropathologica Communications</i> , 2015, 3, 53.	2.4	25
15	Etiology and Progression of Parkinson's Disease: Cross-Talk Between Environmental Factors and Genetic Vulnerability. <i>Handbook of Behavioral Neuroscience</i> , 2016, 24, 803-819.	0.7	1
16	G2019S Mutation of LRRK2 Increases Autophagy via MEK/ERK Pathway. , 2016, , 123-142.		2
17	A Rapid, Semi-Quantitative Assay to Screen for Modulators of Alpha-Synuclein Oligomerization Ex vivo. <i>Frontiers in Neuroscience</i> , 2015, 9, 511.	1.4	5
18	Unconventional Protein Secretion in Animal Cells. <i>Methods in Molecular Biology</i> , 2016, 1459, 31-46.	0.4	19

#	ARTICLE	IF	CITATIONS
19	Alpha-synuclein (SNCA) polymorphisms exert protective effects on memory after mild traumatic brain injury. <i>Neuroscience Letters</i> , 2016, 630, 241-246.	1.0	3
20	Parkinson Disease and Dementia. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2016, 29, 261-270.	1.2	52
21	Review: Sporadic Parkinson's disease: development and distribution of α -synuclein pathology. <i>Neuropathology and Applied Neurobiology</i> , 2016, 42, 33-50.	1.8	309
22	Mutations associated with familial Parkinson's disease alter the initiation and amplification steps of α -synuclein aggregation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 10328-10333.	3.3	252
23	Recent developments in circulating biomarkers in Parkinson's disease: the potential use of miRNAs in a clinical setting. <i>Bioanalysis</i> , 2016, 8, 2497-2518.	0.6	16
24	The effects of the novel A53E alpha-synuclein mutation on its oligomerization and aggregation. <i>Acta Neuropathologica Communications</i> , 2016, 4, 128.	2.4	35
25	Next-generation sequencing reveals substantial genetic contribution to dementia with Lewy bodies. <i>Neurobiology of Disease</i> , 2016, 94, 55-62.	2.1	55
26	Development of passive immunotherapies for synucleinopathies. <i>Movement Disorders</i> , 2016, 31, 203-213.	2.2	79
27	Neuropathological relationship between major depression and dementia: A hypothetical model and review. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2016, 67, 51-57.	2.5	89
28	Up-regulation of SNCA gene expression: implications to synucleinopathies. <i>Neurogenetics</i> , 2016, 17, 145-157.	0.7	56
29	The analysis of association between SNCA, HUSEYO and CSMD1 gene variants and Parkinson's disease in Iranian population. <i>Neurological Sciences</i> , 2016, 37, 731-736.	0.9	20
30	Transcriptome profiling in Parkinson's leukocytes: from early diagnostics to neuroimmune therapeutic prospects. <i>Current Opinion in Pharmacology</i> , 2016, 26, 102-109.	1.7	12
31	Amyloid- β suppresses AMP-activated protein kinase (AMPK) signaling and contributes to α -synuclein-induced cytotoxicity. <i>Experimental Neurology</i> , 2016, 275, 84-98.	2.0	32
33	An enhanced recombinant amino-terminal acetylation system and novel <i>in vivo</i> high-throughput screen for molecules affecting α -synuclein oligomerisation. <i>FEBS Letters</i> , 2017, 591, 833-841.	1.3	18
34	Mechanisms of Parkinson's disease-related proteins in mediating secondary brain damage after cerebral ischemia. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2017, 37, 1910-1926.	2.4	51
35	PI3K/AKT signaling mediated by G protein-coupled receptors is involved in neurodegenerative Parkinson's disease (Review). <i>International Journal of Molecular Medicine</i> , 2017, 39, 253-260.	1.8	72
37	Validating the Predicted Effect of Astemizole and Ketoconazole Using a <i>Drosophila</i> Model of Parkinson's Disease. <i>Assay and Drug Development Technologies</i> , 2017, 15, 106-112.	0.6	9
38	Immune and myodegenerative pathomechanisms in inclusion body myositis. <i>Annals of Clinical and Translational Neurology</i> , 2017, 4, 422-445.	1.7	41

#	ARTICLE	IF	CITATIONS
39	Cross talk between neurometals and amyloidogenic proteins at the synapse and the pathogenesis of neurodegenerative diseases. <i>Metallomics</i> , 2017, 9, 619-633.	1.0	55
40	Inflammatory pre-conditioning restricts the seeded induction of α -synuclein pathology in wild type mice. <i>Molecular Neurodegeneration</i> , 2017, 12, 1.	4.4	104
41	Current understanding of the molecular mechanisms in Parkinson's disease: Targets for potential treatments. <i>Translational Neurodegeneration</i> , 2017, 6, 28.	3.6	353
42	A Systems Model of Parkinson's Disease Using Biochemical Systems Theory. <i>OMICS A Journal of Integrative Biology</i> , 2017, 21, 454-464.	1.0	14
43	Small-molecule PET Tracers for Imaging Proteinopathies. <i>Seminars in Nuclear Medicine</i> , 2017, 47, 553-575.	2.5	91
44	Cytokine profiling in the prefrontal cortex of Parkinson's Disease and Multiple System Atrophy patients. <i>Neurobiology of Disease</i> , 2017, 106, 269-278.	2.1	58
45	A pH-dependent switch promotes β -synuclein fibril formation via glutamate residues. <i>Journal of Biological Chemistry</i> , 2017, 292, 16368-16379.	1.6	41
46	Minimal Nucleation State of α -Synuclein Is Stabilized by Dynamic Threonine-Water Networks. <i>ACS Chemical Neuroscience</i> , 2017, 8, 1859-1864.	1.7	10
47	Polo-like kinase 2 modulates α -synuclein protein levels by regulating its mRNA production. <i>Neurobiology of Disease</i> , 2017, 106, 49-62.	2.1	21
48	Alpha-synuclein and oxidative stress enzymes as biomarkers of Parkinson's disease. <i>Neurochemical Journal</i> , 2017, 11, 121-128.	0.2	0
49	Circular RNA: a new star in neurological diseases. <i>International Journal of Neuroscience</i> , 2017, 127, 726-734.	0.8	50
50	Mini-review on initiatives to interfere with the propagation and clearance of alpha-synuclein in Parkinson's disease. <i>Translational Neurodegeneration</i> , 2017, 6, 33.	3.6	10
51	Metabolic Investigations of the Molecular Mechanisms Associated with Parkinson's Disease. <i>Metabolites</i> , 2017, 7, 22.	1.3	39
53	Hypermethylation of Synphilin-1, Alpha-Synuclein-Interacting Protein (SNCAIP) Gene in the Cerebral Cortex of Patients with Sporadic Parkinson's Disease. <i>Brain Sciences</i> , 2017, 7, 74.	1.1	9
54	Refinement of a neuronal differentiation protocol predominantly yields human iPS cell-derived dopaminergic neurons for the investigation of neurodegenerative pathomechanisms in vitro. <i>Journal of Cellular Biotechnology</i> , 2017, 3, 61-80.	0.1	0
55	Autonomic dysfunction in genetic forms of synucleinopathies. <i>Movement Disorders</i> , 2018, 33, 359-371.	2.2	17
56	Regulation of the Extracellular Matrix by Heat Shock Proteins and Molecular Chaperones. , 2018, , 97-121.		1
57	When Do α -Synucleinopathies Start? An Epidemiological Timeline. <i>JAMA Neurology</i> , 2018, 75, 503.	4.5	69

#	ARTICLE	IF	CITATIONS
58	Prion-like properties of disease-relevant proteins in amyotrophic lateral sclerosis. <i>Journal of Neural Transmission</i> , 2018, 125, 591-613.	1.4	16
59	Overactive BRCA1 Affects Presenilin 1 in Induced Pluripotent Stem Cell-Derived Neurons in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 175-202.	1.2	36
60	Are dementia with Lewy bodies and Parkinson's disease dementia the same disease?. <i>BMC Medicine</i> , 2018, 16, 34.	2.3	232
61	Decreased expression of serum- and glucocorticoid-inducible kinase 1 (SGK1) promotes alpha-synuclein increase related with down-regulation of dopaminergic cell in the Substantia Nigra of chronic MPTP-induced Parkinsonism mice and in SH-SY5Y cells. <i>Gene</i> , 2018, 661, 189-195.	1.0	8
63	Distinct β -Synuclein strains and implications for heterogeneity among β -Synucleinopathies. <i>Neurobiology of Disease</i> , 2018, 109, 209-218.	2.1	121
64	$A\beta$ exacerbates β -synuclein-induced neurotoxicity through impaired insulin signaling in β -synuclein-overexpressed human SK-N-BE neuronal cells. <i>CNS Neuroscience and Therapeutics</i> , 2018, 24, 1.9 47-57.	1.9	8
65	Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies. <i>Journal of Neural Transmission</i> , 2018, 125, 615-650.	1.4	200
66	Multiple System Atrophy: Many Lessons from the Transcriptome. <i>Neuroscientist</i> , 2018, 24, 294-307.	2.6	7
67	miRNA-based signatures in cerebrospinal fluid as potential diagnostic tools for early stage Parkinson's disease. <i>Oncotarget</i> , 2018, 9, 17455-17465.	0.8	94
68	Current state of Alzheimer's fluid biomarkers. <i>Acta Neuropathologica</i> , 2018, 136, 821-853.	3.9	370
69	Targeting GSK3 signaling as a potential therapy of neurodegenerative diseases and aging. <i>Expert Opinion on Therapeutic Targets</i> , 2018, 22, 833-848.	1.5	83
70	Clearing Extracellular Alpha-Synuclein from Cerebrospinal Fluid: A New Therapeutic Strategy in Parkinson's Disease. <i>Brain Sciences</i> , 2018, 8, 52.	1.1	13
71	An Inducible Alpha-Synuclein Expressing Neuronal Cell Line Model for Parkinson's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 453-460.	1.2	11
72	Major or Mild Neurocognitive Disorders with Lewy Bodies. , 2018, , 429-443.		0
73	Distinct Mechanisms of Pathogenic DJ-1 Mutations in Mitochondrial Quality Control. <i>Frontiers in Molecular Neuroscience</i> , 2018, 11, 68.	1.4	25
74	Sirt-2.1 mediated attenuation of β -synuclein expression by Alaskan bog blueberry polyphenols in a transgenic model of <i>Caenorhabditis elegans</i> . <i>Scientific Reports</i> , 2018, 8, 10216.	1.6	17
75	Co-aggregation of pro-inflammatory S100A9 with β -synuclein in Parkinson's disease: ex vivo and in vitro studies. <i>Journal of Neuroinflammation</i> , 2018, 15, 172.	3.1	50
76	Implications of Metal Binding and Asparagine Deamidation for Amyloid Formation. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2449.	1.8	15

#	ARTICLE	IF	CITATIONS
77	Ceftriaxone Treatment for Neuronal Deficits: A Histological and MEMRI Study in a Rat Model of Dementia with Lewy Bodies. <i>Behavioural Neurology</i> , 2018, 2018, 1-9.	1.1	11
78	Ammonâ€™s Horn 2 (CA2) of the Hippocampus: A Long-Known Region with a New Potential Role in Neurodegeneration. <i>Neuroscientist</i> , 2019, 25, 167-180.	2.6	37
79	Dementia associated with disorders of the basal ganglia. <i>Journal of Neuroscience Research</i> , 2019, 97, 1728-1741.	1.3	10
80	The Landscape of SNCA Transcripts Across Synucleinopathies: New Insights From Long Reads Sequencing Analysis. <i>Frontiers in Genetics</i> , 2019, 10, 584.	1.1	15
81	<i>STXBP1</i> encephalopathy. <i>Neurology</i> , 2019, 93, 114-123.	1.5	37
82	Prion-Like Mechanisms in Parkinsonâ€™s Disease. <i>Frontiers in Neuroscience</i> , 2019, 13, 552.	1.4	88
83	Injection of Î±-syn-98 Aggregates Into the Brain Triggers Î±-Synuclein Pathology and an Inflammatory Response. <i>Frontiers in Molecular Neuroscience</i> , 2019, 12, 189.	1.4	7
84	Iron Redox Chemistry and Implications in the Parkinsonâ€™s Disease Brain. <i>Oxidative Medicine and Cellular Longevity</i> , 2019, 2019, 1-11.	1.9	25
85	Initiation and Transmission of Î±-Synuclein Pathology in Parkinsonâ€™s Disease. <i>Neurochemical Research</i> , 2019, 44, 2685-2694.	1.6	6
86	Ginkgolic acid promotes autophagy-dependent clearance of intracellular alpha-synuclein aggregates. <i>Molecular and Cellular Neurosciences</i> , 2019, 101, 103416.	1.0	30
87	Neurodegenerative Diseases and Their Therapeutic Approaches. , 0, , .		1
88	Synaptic vesicle mimics affect the aggregation of wild-type and A53T Î±-synuclein variants differently albeit similar membrane affinity. <i>Protein Engineering, Design and Selection</i> , 2019, 32, 59-66.	1.0	6
89	Impairment of Nrf2- and Nitric-Oxide-Mediated Gastrointestinal Motility in an MPTP Mouse Model of Parkinsonâ€™s Disease. <i>Digestive Diseases and Sciences</i> , 2019, 64, 3502-3517.	1.1	12
90	Use of Ceftriaxone in Treating Cognitive and Neuronal Deficits Associated With Dementia With Lewy Bodies. <i>Frontiers in Neuroscience</i> , 2019, 13, 507.	1.4	9
91	Erectile Dysfunction Preceding Clinically Diagnosed Î±-Synucleinopathies: A Case-Control Study in Olmsted County. <i>Parkinson's Disease</i> , 2019, 2019, 1-6.	0.6	7
92	Acupuncture Inhibits the Increase in Alpha-Synuclein by Modulating SGK1 in an MPTP Induced Parkinsonism Mouse Model. <i>The American Journal of Chinese Medicine</i> , 2019, 47, 527-539.	1.5	9
93	Neurochemical Aspects of Lewy Body Dementia. , 2019, , 113-150.		0
94	Neurochemical Aspects of Neurological Disorders. , 2019, , 1-22.		1

#	ARTICLE	IF	CITATIONS
95	Curcumin in Neurological Disorders: An Overview. , 2019, , 63-84.		1
96	Therapeutic Potentials of Curcumin in Parkinsonâ€™s Disease. , 2019, , 333-344.		4
97	AAA+ Protein-Based Technologies to Counter Neurodegenerative Disease. Biophysical Journal, 2019, 116, 1380-1385.	0.2	17
98	Î±-Synuclein and astrocytes: tracing the pathways from homeostasis to neurodegeneration in Lewy body disease. Acta Neuropathologica, 2019, 138, 1-21.	3.9	109
99	A new avenue for treating neuronal diseases: Ceftriaxone, an old antibiotic demonstrating behavioral neuronal effects. Behavioural Brain Research, 2019, 364, 149-156.	1.2	26
100	Protein misfolding and aggregation in neurodegenerative diseases: a review of pathogeneses, novel detection strategies, and potential therapeutics. Reviews in the Neurosciences, 2019, 30, 339-358.	1.4	84
101	rAAV-based brain slice culture models of Alzheimerâ€™s and Parkinsonâ€™s disease inclusion pathologies. Journal of Experimental Medicine, 2019, 216, 539-555.	4.2	48
102	Physiological, molecular and genetic aspects of alpha-synuclein and its correlation with high alcohol consumption. Revista Facultad De Medicina, 2019, 67, 315-322.	0.0	0
103	Mitochondrial dynamics, a key executioner in neurodegenerative diseases. Mitochondrion, 2019, 47, 151-173.	1.6	85
104	Heterogeneity in Î±-synuclein subtypes and their expression in cortical brain tissue lysates from Lewy body diseases and Alzheimer's disease. Neuropathology and Applied Neurobiology, 2019, 45, 597-608.	1.8	27
105	When safeguarding goes wrong: Impact of oxidative stress on protein homeostasis in health and neurodegenerative disorders. Advances in Protein Chemistry and Structural Biology, 2019, 114, 221-264.	1.0	13
106	Quantification of Protein Aggregates Using Bimolecular Fluorescence Complementation. Methods in Molecular Biology, 2019, 1873, 183-193.	0.4	0
107	Available and future treatments for atypical parkinsonism. A systematic review. CNS Neuroscience and Therapeutics, 2019, 25, 159-174.	1.9	22
108	Effects of curcumin on mitochondria in neurodegenerative diseases. BioFactors, 2020, 46, 5-20.	2.6	100
109	Structural analysis of the effects of mutations in Ubl domain of Parkin leading to Parkinsonâ€™s disease. Gene, 2020, 726, 144186.	1.0	12
110	Glycogen synthase kinase 3 Î² activity is essential for Polo-like kinase 2- and Leucine-rich repeat kinase 2-mediated regulation of Î±-synuclein. Neurobiology of Disease, 2020, 136, 104720.	2.1	9
111	Antioxidants and Nanotechnology: Promises and Limits of Potentially Disruptive Approaches in the Treatment of Central Nervous System Diseases. Advanced Healthcare Materials, 2020, 9, e1901589.	3.9	50
112	Molecular mechanism of olesoxime-mediated neuroprotection through targeting Î±-synuclein interaction with mitochondrial VDAC. Cellular and Molecular Life Sciences, 2020, 77, 3611-3626.	2.4	39

#	ARTICLE	IF	CITATIONS
113	High-Resolution Respirometry Reveals MPP+ Mitochondrial Toxicity Mechanism in a Cellular Model of Parkinson's Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7809.	1.8	37
114	The Role of Glial Mitochondria in α -Synuclein Toxicity. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 548283.	1.8	13
115	Roles, Characteristics, and Analysis of Intrinsically Disordered Proteins: A Minireview. <i>Life</i> , 2020, 10, 320.	1.1	11
116	Anti-prion and α -Synuclein Aggregation Inhibitory Sterols from the Sponge <i>Chlorella</i> cf. <i>Chlorella</i> . <i>Journal of Natural Products</i> , 2020, 83, 3751-3757.	1.5	8
117	Influence of serum concentration in retinoic acid and phorbol ester induced differentiation of SH-SY5Y human neuroblastoma cell line. <i>Molecular Biology Reports</i> , 2020, 47, 8775-8788.	1.0	9
118	Amyloid and Amyloid-Like Aggregates: Diversity and the Term Crisis. <i>Biochemistry (Moscow)</i> , 2020, 85, 1011-1034.	0.7	17
119	The role of natural killer cells in Parkinson's disease. <i>Experimental and Molecular Medicine</i> , 2020, 52, 1517-1525.	3.2	42
120	BAG5 Promotes Alpha-Synuclein Oligomer Formation and Functionally Interacts With the Autophagy Adaptor Protein p62. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 716.	1.8	6
121	Copper Dyshomeostasis in Neurodegenerative Diseases—Therapeutic Implications. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9259.	1.8	125
122	Nanotheranostic Applications for Detection and Targeting Neurodegenerative Diseases. <i>Frontiers in Neuroscience</i> , 2020, 14, 305.	1.4	41
123	Insulin resistance and Parkinson's disease. , 2020, , 293-347.		0
124	Targeting the Multiple Physiologic Roles of VDAC With Steroids and Hydrophobic Drugs. <i>Frontiers in Physiology</i> , 2020, 11, 446.	1.3	24
125	Dual Targeting of Monomeric Tau and α -Synuclein Aggregation: A New Multitarget Therapeutic Strategy for Neurodegeneration. <i>ACS Chemical Neuroscience</i> , 2020, 11, 2051-2057.	1.7	13
126	LRRK2-Related Parkinson's Disease Due to Altered Endolysosomal Biology With Variable Lewy Body Pathology: A Hypothesis. <i>Frontiers in Neuroscience</i> , 2020, 14, 556.	1.4	19
127	Inhibition of alpha-synuclein seeded fibril formation and toxicity by herbal medicinal extracts. <i>BMC Complementary Medicine and Therapies</i> , 2020, 20, 73.	1.2	22
128	How We Think about Targeting RNA with Small Molecules. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 8880-8900.	2.9	109
129	Fatty Acid Binding Protein 3 Enhances the Spreading and Toxicity of α -Synuclein in Mouse Brain. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2230.	1.8	28
130	Cynomolgus Monkeys With Spontaneous Type-2-Diabetes-Mellitus-Like Pathology Develop Alpha-Synuclein Alterations Reminiscent of Prodromal Parkinson's Disease and Related Diseases. <i>Frontiers in Neuroscience</i> , 2020, 14, 63.	1.4	17

#	ARTICLE	IF	CITATIONS
131	Perspective: Current Pitfalls in the Search for Future Treatments and Prevention of Parkinson's Disease. <i>Frontiers in Neurology</i> , 2020, 11, 686.	1.1	6
133	Orderâ€ disorder skewness in alpha-synuclein: a key mechanism to recognize membrane curvature. <i>Physical Chemistry Chemical Physics</i> , 2020, 22, 5255-5263.	1.3	16
134	miRNA-31 Improves Cognition and Abolishes Amyloid-Î² Pathology by Targeting APP and BACE1 in an Animal Model of Alzheimerâ€™s Disease. <i>Molecular Therapy - Nucleic Acids</i> , 2020, 19, 1219-1236.	2.3	56
135	Fineâ€ Mapping of <i>SNCA</i> in Rapid Eye Movement Sleep Behavior Disorder and Overt Synucleinopathies. <i>Annals of Neurology</i> , 2020, 87, 584-598.	2.8	39
136	Targeting microglial autophagic degradation in NLRP3 inflammasome-mediated neurodegenerative diseases. <i>Ageing Research Reviews</i> , 2021, 65, 101202.	5.0	104
137	Biophysical processes underlying cross-seeding in amyloid aggregation and implications in amyloid pathology. <i>Biophysical Chemistry</i> , 2021, 269, 106507.	1.5	101
138	Isolongifolene mitigates rotenone-induced dopamine depletion and motor deficits through anti-oxidative and anti-apoptotic effects in a rat model of Parkinson's disease. <i>Journal of Chemical Neuroanatomy</i> , 2021, 112, 101890.	1.0	20
139	Inflammation and Parkinson's disease pathogenesis: Mechanisms and therapeutic insight. <i>Progress in Molecular Biology and Translational Science</i> , 2021, 177, 175-202.	0.9	21
140	Gut-Brain axis in Parkinson's disease etiology: The role of lipopolysaccharide. <i>Chemistry and Physics of Lipids</i> , 2021, 235, 105029.	1.5	20
141	Analysis of Î±-synuclein levels related to LRRK2 kinase activity: from substantia nigra to urine of patients with Parkinsonâ€™s disease. <i>Animal Cells and Systems</i> , 2021, 25, 28-36.	0.8	8
142	Correlation between Alzheimerâ€™s Disease and Dementia with Lewy Bodies Scores Using VSRAD Advance. <i>Advances in Alzheimer's Disease</i> , 2021, 10, 33-45.	0.3	0
144	Role of Medicinal Plants against Neurodegenerative Diseases. <i>Current Pharmaceutical Biotechnology</i> , 2022, 23, 123-139.	0.9	18
145	Heterogeneity in Î±-synuclein fibril activity correlates to disease phenotypes in Lewy body dementia. <i>Acta Neuropathologica</i> , 2021, 141, 547-564.	3.9	23
146	Cerebrospinal Fluid Biomarkers of Alzheimerâ€™s Disease: Current Evidence and Future Perspectives. <i>Brain Sciences</i> , 2021, 11, 215.	1.1	58
147	Mind the Gap: Mitochondria and the Endoplasmic Reticulum in Neurodegenerative Diseases. <i>Biomedicines</i> , 2021, 9, 227.	1.4	25
148	Docosahexaenoic and Arachidonic Acids as Neuroprotective Nutrients throughout the Life Cycle. <i>Nutrients</i> , 2021, 13, 986.	1.7	63
149	Fasâ€ associated factor 1 induces the accumulation of Î±-synuclein through autophagic suppression in dopaminergic neurons. <i>FASEB Journal</i> , 2021, 35, e21363.	0.2	2
150	The Neurophysiology of Sleep in Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 1526-1542.	2.2	34

#	ARTICLE	IF	CITATIONS
151	Genome instability and loss of protein homeostasis: converging paths to neurodegeneration?. <i>Open Biology</i> , 2021, 11, 200296.	1.5	26
152	Interactions of α -synuclein oligomers with lipid membranes. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2021, 1863, 183536.	1.4	49
153	The Contribution of Microglia to Neuroinflammation in Parkinson's Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4676.	1.8	114
154	Prion-like C-Terminal Domain of TDP-43 and α -Synuclein Interact Synergistically to Generate Neurotoxic Hybrid Fibrils. <i>Journal of Molecular Biology</i> , 2021, 433, 166953.	2.0	40
155	α -Synuclein emerges as a potent regulator of VDAC-facilitated calcium transport. <i>Cell Calcium</i> , 2021, 95, 102355.	1.1	27
157	α -Janus-Faced α -Synuclein: Role in Parkinson's Disease. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 673395.	1.8	8
158	The <i>O</i> -Glycome of Human Nigrostriatal Tissue and Its Alteration in Parkinson's Disease. <i>Journal of Proteome Research</i> , 2021, 20, 3913-3924.	1.8	20
159	Poly (ADP-ribose) Interacts With Phosphorylated α -Synuclein in Post Mortem PD Samples. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 704041.	1.7	14
160	Parkinson's Disease: A Prionopathy?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8022.	1.8	12
161	Modulation of the Interactions Between α -Synuclein and Lipid Membranes by Post-translational Modifications. <i>Frontiers in Neurology</i> , 2021, 12, 661117.	1.1	23
162	Parkinson's Disease and the Gut: Symptoms, Nutrition, and Microbiota. <i>Journal of Parkinson's Disease</i> , 2021, 11, 1491-1505.	1.5	21
163	The Impact of SNCA Variations and Its Product Alpha-Synuclein on Non-Motor Features of Parkinson's Disease. <i>Life</i> , 2021, 11, 804.	1.1	10
164	Association of lewy bodies, hippocampal sclerosis and amyloid angiopathy with dementia in community-dwelling elderly: A systematic review and meta-analysis. <i>Journal of Clinical Neuroscience</i> , 2021, 90, 124-131.	0.8	1
165	<i>RNA</i> ligand molecular docking: Advances and challenges. <i>Wiley Interdisciplinary Reviews: Computational Molecular Science</i> , 2022, 12, e1571.	6.2	20
166	Mass spectrometry-based methods for robust measurement of Alzheimer's disease biomarkers in biological fluids. <i>Journal of Neurochemistry</i> , 2021, 159, 211-233.	2.1	29
167	A novel yeast-based screening system for potential compounds that can alleviate human α -synuclein toxicity. <i>Journal of Applied Microbiology</i> , 2021, , .	1.4	3
168	Modelling the functional genomics of Parkinson's disease in <i>Caenorhabditis elegans</i> : <i>LRRK2</i> and beyond. <i>Bioscience Reports</i> , 2021, 41, .	1.1	8
169	The role of neuroimaging in Parkinson's disease. <i>Journal of Neurochemistry</i> , 2021, 159, 660-689.	2.1	35

#	ARTICLE	IF	CITATIONS
170	Role of Inflammation in Lewy Body Dementia. , 2021, , 190-212.		0
171	Imaging of Î±-Synuclein Aggregates in a Rat Model of Parkinsonâ€™s Disease Using Raman Microspectroscopy. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 664365.	1.8	5
172	Contribution of neuroinflammation, resolution, and neuroprotection in neurodegenerative diseases. , 2022, , 121-160.		0
173	QSAR and QAAR Studies on Mixtures of 3-(Benzylidene)Indolin-2-One Isomers as Leads to Develop PET Radiotracers for Detection of Parkinson's Disease. , 2021, , 366-385.		0
174	Liposomes loaded with polyphenol-rich grape pomace extracts protect from neurodegeneration in a rotenone-based <i>in vitro</i> model of Parkinson's disease. <i>Biomaterials Science</i> , 2021, 9, 8171-8188.	2.6	18
175	Ferrosenescence: The iron age of neurodegeneration?. <i>Mechanisms of Ageing and Development</i> , 2018, 174, 63-75.	2.2	56
176	The emerging role of Î±-synuclein truncation in aggregation and disease. <i>Journal of Biological Chemistry</i> , 2020, 295, 10224-10244.	1.6	99
178	Development of a diamond waveguide sensor for sensitive protein analysis using IR quantum cascade lasers. , 2018, , .		5
179	Magnetic resonance imaging and tensor-based morphometry in the MPTP non-human primate model of Parkinsonâ€™s disease. <i>PLoS ONE</i> , 2017, 12, e0180733.	1.1	9
180	Quantitative proteomics in A30P*A53T Î±-synuclein transgenic mice reveals upregulation of Sel1l. <i>PLoS ONE</i> , 2017, 12, e0182092.	1.1	9
181	Modeling Î±-Synuclein Propagation with Preformed Fibril Injections. <i>Journal of Movement Disorders</i> , 2019, 12, 139-151.	0.7	65
182	Chronic exposure to cerebrospinal fluid of multiple system atrophy in neuroblastoma and glioblastoma cells induces cytotoxicity via ER stress and autophagy activation. <i>Oncotarget</i> , 2015, 6, 13278-13294.	0.8	6
183	Key Peptides and Proteins in Alzheimerâ€™s Disease. <i>Current Protein and Peptide Science</i> , 2019, 20, 577-599.	0.7	30
184	Advances in Studies on Stroke-Induced Secondary Neurodegeneration (SND) and Its Treatment. <i>Current Topics in Medicinal Chemistry</i> , 2020, 20, 1154-1168.	1.0	10
185	Therapeutic genetic variation revealed in diverse Hsp104 homologs. <i>ELife</i> , 2020, 9, .	2.8	17
186	Recent advances in nanosensors development for biomarker alpha-synuclein protein detection. <i>Process Biochemistry</i> , 2021, 111, 105-113.	1.8	7
187	Polo-like kinase 2 inhibition reduces serine-129 phosphorylation of physiological nuclear alpha-synuclein but not of the aggregated alpha-synuclein. <i>PLoS ONE</i> , 2021, 16, e0252635.	1.1	18
188	Computational Approach towards Targeting Aggregate Formation in Synucleinopathies. <i>MOJ Proteomics & Bioinformatics</i> , 2015, 2, .	0.1	0

#	ARTICLE	IF	CITATIONS
189	Transmission Mechanism of Lewy Body-Like α -Synucleinopathies in Dopaminergic Neurons Derived from Human Induced Pluripotent Stem Cells. <i>Research Ideas and Outcomes</i> , 0, 4, e25423.	1.0	0
191	QSAR and QAAR Studies on Mixtures of 3-(Benzylidene)Indolin-2-One Isomers as Leads to Develop PET Radiotracers for Detection of Parkinson's Disease. <i>International Journal of Quantitative Structure-Property Relationships</i> , 2018, 3, 95-114.	1.1	1
193	Neurodegenerative Diseases: Lewy Body Dementia. , 2019, , 933-944.		0
195	Chronic α -Synuclein Accumulation in Rat Hippocampus Induces Lewy Bodies Formation and Specific Cognitive Impairments. <i>ENeuro</i> , 2020, 7, ENEURO.0009-20.2020.	0.9	11
199	Promising molecular targets for pharmacological therapy of neurodegenerative pathologies. <i>Acta Naturae</i> , 2020, 12, 60-80.	1.7	3
201	Evidence that the Kennedy and polyamine pathways are dysregulated in human brain in cases of dementia with Lewy bodies. <i>Brain Research</i> , 2020, 1743, 146897.	1.1	5
202	Dementia with Lewy bodies and Parkinson's disease dementia-two independent disorders or one clinical entity within a clinical spectrum of synucleinopathies?. <i>Current Problems of Psychiatry</i> , 2020, 21, 161-166.	0.1	0
203	Clinical and Biochemical Heterogeneity of Parkinson's Disease. <i>Neuroscience and Behavioral Physiology</i> , 2021, 51, 1073-1078.	0.2	0
204	O-GlcNAcylation in health and neurodegenerative diseases. <i>Experimental and Molecular Medicine</i> , 2021, 53, 1674-1682.	3.2	53
205	Sycosterol A, an α -Synuclein Inhibitory Sterol from the Australian Ascidian <i>Sycozoa cerebriformis</i> . <i>Journal of Natural Products</i> , 2021, 84, 3039-3043.	1.5	6
206	Fat and Protein Combat Triggers Immunological Weapons of Innate and Adaptive Immune Systems to Launch Neuroinflammation in Parkinson's Disease. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1089.	1.8	4
208	Insights into the Interactions that Trigger the Primary Nucleation of Polymorphic α -Synuclein Dimers. <i>ACS Chemical Neuroscience</i> , 2022, 13, 370-378.	1.7	10
209	Time-Course of Alterations in the Endocannabinoid System after Viral-Mediated Overexpression of α -Synuclein in the Rat Brain. <i>Molecules</i> , 2022, 27, 507.	1.7	6
210	Upregulation of α -synuclein following immune activation: Possible trigger of Parkinson's disease. <i>Neurobiology of Disease</i> , 2022, 166, 105654.	2.1	27
211	Leukotriene Signaling as a Target in α -Synucleinopathies. <i>Biomolecules</i> , 2022, 12, 346.	1.8	5
212	Identification of α -Synuclein Disaggregator from <i>Camellia sp.</i> . Insight of Molecular Docking and Molecular Dynamics Simulations. <i>ChemistrySelect</i> , 2022, 7, .	0.7	2
213	Pathological Relevance of Post-Translationally Modified Alpha-Synuclein (pSer87, pSer129, nTyr39) in Idiopathic Parkinson's Disease and Multiple System Atrophy. <i>Cells</i> , 2022, 11, 906.	1.8	14
214	Network Theoretical Approach to Explore Factors Affecting Signal Propagation and Stability in Dementia's Protein-Protein Interaction Network. <i>Biomolecules</i> , 2022, 12, 451.	1.8	11

#	ARTICLE	IF	CITATIONS
215	Associations between cerebrospinal fluid markers and cognition in ageing and dementia: A systematic review. <i>European Journal of Neuroscience</i> , 2022, 56, 5650-5713.	1.2	4
216	Chapter 5 " "Parkinson's disease " A role of non-enzymatic posttranslational modifications in disease onset and progression?" <i>Molecular Aspects of Medicine</i> , 2022, 86, 101096.	2.7	8
217	Î±-Synuclein arginylation in the human brain. <i>Translational Neurodegeneration</i> , 2022, 11, 20.	3.6	8
229	The Role of Alpha-Synuclein Autoantibodies in the Induction of Brain Inflammation and Neurodegeneration in Aged Humans. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	3
230	Dysregulation of a Heme Oxygenase"Synuclein Axis in Parkinson Disease. <i>NeuroSci</i> , 2022, 3, 284-299.	0.4	2
231	Curcumin-loaded human endometrial stem cells derived exosomes as an effective carrier to suppress alpha-synuclein aggregates in 6OHDA-induced Parkinson"™s disease mouse model. <i>Cell and Tissue Banking</i> , 2023, 24, 75-91.	0.5	13
232	The Value of Neuroimaging in Dementia Diagnosis. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2022, 28, 800-821.	0.4	2
233	GANAB and N-Glycans Substrates Are Relevant in Human Physiology, Polycystic Pathology and Multiple Sclerosis: A Review. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7373.	1.8	4
234	Frontal Atrophy and Executive Dysfunction Relate to Complex Numbers Impairment in Progressive Supranuclear Palsy. <i>Journal of Alzheimer's Disease</i> , 2022, 88, 1553-1566.	1.2	2
235	Therapeutic Strategies for Immune Transformation in Parkinson"™s Disease. <i>Journal of Parkinson's Disease</i> , 2022, 12, S201-S222.	1.5	7
236	Polymorphism in alpha-synuclein oligomers and its implications in toxicity under disease conditions. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	6
237	Cocoa Extract Provides Protection against 6-OHDA Toxicity in SH-SY5Y Dopaminergic Neurons by Targeting PERK. <i>Biomedicines</i> , 2022, 10, 2009.	1.4	9
238	Role of Impaired Insulin Signaling in the Pathogenesis of Dementia. , 2022, , 63-84.		0
239	Interplay of alpha-synuclein pathology and gut microbiome in Parkinson"™s disease. , 2022, , 159-178.		1
240	Resveratrol: A potential therapeutic natural polyphenol for neurodegenerative diseases associated with mitochondrial dysfunction. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	15
241	Gut dysfunction may be the source of pathological aggregation of alpha-synuclein in the central nervous system through Paraquat exposure in mice. <i>Ecotoxicology and Environmental Safety</i> , 2022, 246, 114152.	2.9	6
242	The Role of Inflammasomes in the Pathogenesis of Neurodegenerative Diseases. <i>Neurochemical Journal</i> , 2022, 16, 271-282.	0.2	0
243	Surgical Management of Synucleinopathies. <i>Biomedicines</i> , 2022, 10, 2657.	1.4	2

#	ARTICLE	IF	CITATIONS
244	Influence of TiO ₂ and ZnO Nanoparticles on α -Synuclein and $A\beta$ -Amyloid Aggregation and Formation of Protein Fibrils. <i>Materials</i> , 2022, 15, 7664.	1.3	4
245	Gastric Enteric Glial Cells: A New Contributor to the Synucleinopathies in the MPTP-Induced Parkinsonism Mouse. <i>Molecules</i> , 2022, 27, 7414.	1.7	3
246	How binding to surfaces affects disorder?. , 2023, , 455-489.		2
247	Recent development of analytical methods for disease-specific protein <i>O</i> -GlcNAcylation. <i>RSC Advances</i> , 2022, 13, 264-280.	1.7	4
248	The Effects of Dietary Interventions on Brain Aging and Neurological Diseases. <i>Nutrients</i> , 2022, 14, 5086.	1.7	9
249	The effect of diphenylethane side-chain substituents on dibenzocyclohexadiene formation and their inhibition of α -synuclein aggregation in vitro. <i>Bioorganic and Medicinal Chemistry</i> , 2023, 78, 117147.	1.4	1
250	Optical pulse labeling studies reveal exogenous seeding slows α -synuclein clearance. <i>Npj Parkinson's Disease</i> , 2022, 8, .	2.5	1
251	Lysophospholipids: A Potential Drug Candidates for Neurodegenerative Disorders. <i>Biomedicines</i> , 2022, 10, 3126.	1.4	3
252	Models of Neurodegenerative Diseases. <i>Learning Materials in Biosciences</i> , 2023, , 179-209.	0.2	0
253	Unravelling the genetic links between Parkinson's disease and lung cancer. <i>Biological Chemistry</i> , 2023, 404, 551-567.	1.2	1
254	Alpha-synuclein: a pathological factor with $A\beta$ and tau and biomarker in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2022, 14, .	3.0	12
255	Novel FABP3 ligand, HY-11-9, ameliorates neuropathological deficits in MPTP-induced Parkinsonism in mice. <i>Journal of Pharmacological Sciences</i> , 2023, 152, 30-38.	1.1	4
256	Inflammation-Mediated Responses in the Development of Neurodegenerative Diseases. <i>Advances in Experimental Medicine and Biology</i> , 2023, , 39-70.	0.8	1
281	Macro and micro-sleep dysfunctions as translational biomarkers for Parkinson's disease. <i>International Review of Neurobiology</i> , 2024, , 187-209.	0.9	0